Skip to main content
. 2024 Nov 19;8:268. doi: 10.1038/s41698-024-00739-y

Fig. 3. DLL3 IHC expression in patient samples with neuroendocrine carcinomas from different origin.

Fig. 3

Representative images of DLL3 IHC staining intensities in four categories from left to right: negative (0), weak (1 + ), moderate (2 + ), and strong (3 + ) lung: small cell lung carcinoma (b) and large cell neuroendocrine carcinoma (a, c, d); uterine cervix: small cell carcinoma (e, f, h), and large cell neuroendocrine carcinoma (g); bladder: small cell carcinoma (i, j, k, l), prostate: AVPC-NEC (m, n, o, p); Merkel cell carcinoma (MCC) of the skin (q, r, s, and t); Head & Neck (H&N): parotid gland neuroendocrine carcinoma (u, x), NEC metastatic from unknowing origin (v), laryngeal neuroendocrine carcinoma (w); and medullary thyroid carcinoma (MTC) (y, z, za, zb) (×40).